@FierceMedDev: Biogen CEO says the biotech aims to develop wearable and ingestible devices. More | Follow @FierceMedDev
@VarunSaxena2: Robotic surgery aspirant receives $4M+ in equity financing. Story | Follow @VarunSaxena2
@EmilyWFierce: ICYMI from FiercePharma: Roche CEO: Despite China worries, emerging markets will continue to deliver growth. Article | Follow @EmilyWFierce
> Boston Scientific ($BSX) has gained a CE mark for its Vercise Primary Cell Deep Brain Stimulation (DBS) System to treat Parkinson's disease, primary and secondary dystonia and essential tremor. The system is in an ongoing U.S. trial. More
> Startup Enable Injections said its wearable injector for subcutaneous drug delivery performed will in a 10-patient, first-in-human trial. More
> OrthoAccel has published data for its AcceleDent device to accelerate tooth movement for during orthodontic treatment. It said that with 20 minutes of daily use, orthodontic treatment was sped up by as much as 50% with the FDA-cleared device. More
Biotech News
@FierceBiotech: Penn scientists identify viral products that defend against respiratory syncytial virus. FierceBiotechResearch story | Follow @FierceBiotech
@JohnCFierce: Who you going to buy? Gilead banks $10B, stirring fresh buzz about a blockbuster buyout. Article | Follow @JohnCFierce
@DamianFierce: Flemming Ornskov, "avid postcard and letter writer" who keeps up on household chores. More | Follow @DamianFierce
> Clovis leaps as AstraZeneca's AZD9291 disappoints on lung cancer. Story
> CureVac turns to Cambridge, MA, to jump-start its mRNA pipeline. Item
> IBM debuts its hotly hyped 'cognitive cloud' health HQ in Cambridge. Article
> Takeda bets $500M on a freshly unstealthed biotech. Report
Pharma News
@FiercePharma: ICYMI yesterday: Ireland plant with 100 workers on Sun's list for sale or closure. Item | Follow @FiercePharma
@EricPFierce: Sun targets Ranbaxy plant in Ireland as it prepares to trim manufacturing network. FiercePharmaManufacturing story | Follow @EricPFierce
@CarlyHFierce: Icahn casts his eye on Vivus with tender offer for convertible notes. More | Follow @CarlyHFierce
> Study: Patients sticking to their scripts saved Medicaid money. More
> Bernie Sanders unveils bill to battle rising drug prices. Article
Vaccines News
> UC Berkeley scientists identify protein that causes dengue shock as a potential vaccine target. Item
> With limited ACIP nod, U.S. universities take different approaches to Pfizer, GSK MenB jabs. Report
> VBI Vaccines scores up to $265,000 from Canadian organization for RSV vaccine. Story
> Analysis: Sanofi's Fluzone High Dose for adults 65+ results in lower medical costs. Article
> Merck's Zostavax not cost-effective for those in their 50s: Study. More
CRO News
> Aragen licenses a protein technology to speed up biologics R&D. Item
> Rho snags a $120M federal contract with NIH. Story
> Recipharm signs on to make LobSor's Parkinson's drug as it negotiates with Novartis. Article
> Icon teams up with IBM to accelerate clinical trial startup. News
> Surging dollar blunts Catalent's revenue, but profits soar in fiscal '15. Article
Pharma Manufacturing News
> Bangladesh-based Square Pharmaceuticals has two new plants online. Item
> Canada allows Apotex Indian plants to regain access to its markets. More
> GSK recalls more than 425K tubes of antibiotic cream. Report
> Sun targets Ranbaxy plant in Ireland as it prepares to trim manufacturing network. Article
> Glaxo starts $153M plant in India. Story
Pharma Asia News
> Japan's Takeda gets U.S. FDA priority review for ixazomib. Item
> FT counts 39 plants banned in India as regulatory woes mount for drugmakers. More
> China Daily carries lengthy industry-linked op-ed against overuse of stents. Report
> Apotex sees Health Canada lift ban on two India plants. Story
> Chugai and Roche get U.S. FDA priority review on alectinib. Article